Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors

BACKGROUND: In patients with epidermal growth factor receptor (EGFR)‐mutated advanced non‐small‐cell lung cancer (NSCLC), epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) treatment has shown a good response. Subsequent treatments jeopardize the ability to determine the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Hisao, Kaira, Kyoichi, Mori, Keita, Kotake, Mie, Mitani, Masumi, Kawashima, Naoko, Hisada, Takeshi, Minato, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885435/
https://www.ncbi.nlm.nih.gov/pubmed/31595714
http://dx.doi.org/10.1111/1759-7714.13193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885435/
https://www.ncbi.nlm.nih.gov/pubmed/31595714
http://dx.doi.org/10.1111/1759-7714.13193

Ejemplares similares